Alectinib and Duvelisib for ALK-positive anaplastic large cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two oral targeted drugs—alectinib and duvelisib—for people whose ALK-positive anaplastic large cell lymphoma has come back or not responded after at least one prior chemotherapy. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ALK-positive anaplastic large cell lymphoma confirmed by standard testing.
- Your lymphoma has returned or not improved after at least one prior treatment that included chemotherapy.
- You are 18 years or older.
- You are able to swallow pills and take medication to prevent a type of pneumonia.
- You have adequate blood counts and kidney and liver function as determined by blood tests.
- You have not had an allogeneic stem cell transplant in the last 6 months or have active graft-versus-host disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
This trial tests a combination of chemotherapy and immunotherapy for children and adults with a type of lymphoma called ALK-positive anaplastic large cell lymphoma that has returned or not responded to previous treatment. The goal is to see if this new approach can help control the disease.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
This trial tests whether giving alectinib (a targeted drug) combined with chemotherapy before surgery can help people with stage III ALK-positive lung cancer that cannot be removed surgically. The goal is to shrink the tumor enough to make surgery possible and improve long-term outcomes.
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
Hear when a new Anaplastic Large Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.